Kindred Biosciences Inc

Kindred Biosciences — Investor Presentation (March 2015)

35 slides from Kindred Biosciences's investor presentation, Mar 24, 2015

  1. Slide 1: KindredBio Best Medicines for Our Best Friends

    KindredBio Best Medicines for Our Best Friends

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements, including but not limited to statements regarding the timing of development for our product candidates, expected commencement and completion of pivotal trials, prospective product candidates, anticipated regulatory app

  3. Slide 3: We Love Our Pet Family Members

    We Love Our Pet Family Members $15.25 billion on veterinary care $1.5 billion on dog knee surgeries $370 million on pet Halloween costumes $700 million on Valentine’s Day gifts Annually, U.S. pet parents estimated to spend: 3

  4. Slide 4: KindredBio

    KindredBio Bring the very best science and medicine to our companion animals. 4

  5. Slide 5: Strategy: Repurpose Human Drugs for Pets

    KindredBio Strategy: Repurpose Human Drugs for Pets Pursue molecules already known to work Reduce technical risk Reduce timelines $3M-$5M to develop each pet drug Reduce financing risk Portfolio approach 5

  6. Slide 6: KindredBio Highlights

    KindredBio Highlights Less than 2 Years to Launch SentiKind for post-operative pain in dogs KIND-012 for fever in horses 2+ launches per year thereafter Attractive Markets Rapidly growing Few current competitors World Class Team Extensive drug development experience Human and veterinary experience D

  7. Slide 7: World Class Leadership Team

    Richard Chin, MD Founder and Chief Executive Officer Former Head of Clinical Research, BioTherapeutics, Genentech Rhodes Scholar World Class Leadership Team Stephen Sundlof, DVM, PhD Senior VP of Regulatory Affairs Former Director, Center for Veterinary Medicine, FDA Denise Bevers​ Founder and Chief

  8. Slide 8: Deep Product Pipeline

    3/23/2015 8 Deep Product Pipeline 8

  9. Slide 9: Key Strengths

    Key Strengths Validated, repurposed molecules Avoid risks associated with new chemical entities Reduced costs and timelines, including for API No royalties/milestones Expertise in biologics In-house clinical development capabilities Reduced costs and timelines by not having to rely on CROs Focus on

  10. Slide 10: Market Opportunity

    Market Opportunity 10

  11. Slide 11: Veterinary Market is Growing Rapidly

    Veterinary Market is Growing Rapidly The veterinary care market grew 65% from 2006 to 2014 Source: APPA Pet Industry Market Size & Ownership Statistics 2014 & TriMark Vet Health Market, June 2013 $9.3 $15.3 $0 $2 $4 $6 $8 $10 $12 $14 $16 $18 2006 2014 Sp e n d in g in B ill ion s 11 Estimated

  12. Slide 12: There is a High Willingness to Pay

    There is a High Willingness to Pay… $500 $1,000 $2,000 $5,000 Extremely/Very likely 62% 42% 35% 22% Somewhat likely 18% 20% 28% 20% Not too likely/Not at all likely 18% 36% 36% 55% Don’t know 1% 2% 1% 3% Pet owners are willing to spend on their seriously ill pets if they require medical treatment So

  13. Slide 13: But Treatment Options are Limited

    …But Treatment Options are Limited Underserved market with attractive growth opportunities Few competing biotechs Large pharma focused on blockbusters On average, less than a dozen pet drugs are approved annually by the FDA In 2014 the FDA approved: 6 pet drugs 41 humans drugs 13

  14. Slide 14: Veterinary Pharmaceuticals Field

    Veterinary Pharmaceuticals Field We believe there are similarities between veterinary pharmaceutical field now and the human pharmaceutical field in its early stages: Similar regulatory standards Similar commercial and reimbursement landscape Similar development costs Numerous untapped opportunities

  15. Slide 15: Veterinary vs. Human Markets

    Veterinary vs. Human Markets Can reach market in 3-5 years Faster Development Lower Development Cost Almost no biotechs, almost no generics Lower Competition Self-Pay Very few reimbursement hurdles Can develop for $3M-$5M per product 15

  16. Slide 16: Programs

    Programs 16

  17. Slide 17: KindredBio Strategy

    KindredBio Strategy Small Molecule Already validated in humans & established manufacturing Customize species- specific dosage and formulate flavored/convenient delivery Biologics Targets based on approved human drugs (e.g., Enbrel and Orencia) Create canine/ feline/equine versions of biologics with

  18. Slide 18: Post-Operative Pain Market

    Post-Operative Pain Market Drugs approved for treatment of post-operative pain in dogs, NSAIDs and narcotics, have significant side effects Many dogs do not respond to NSAIDs NSAIDs can cause bleeding Fentanyl is a controlled narcotic and pets are often kept in the hospital while receiving it Fentan

  19. Slide 19: SentiKind

    SentiKind SentiKind (flupirtine) is a centrally acting non-opioid, non- NSAID, and non-steroidal analgesic The active ingredient in SentiKind is approved outside the United States for short-term treatment of pain in humans 19 0 2 4 6 8 Pretreatment Posttreatment Pa in I n te n s it y i n h u ma n s

  20. Slide 20: SentiKind – Development Status

    SentiKind – Development Status Pivotal field study initiated in post-operative pain in dogs (expect to report results in 2H 2015) Other indications: Post-operative pain in cats Osteoarthritis in dogs 20

  21. Slide 21: KIND-012

    KIND-012 IV and oral drug for treating fever in horses Completing formulation work PK study completed Pilot study completed High unmet medical need Over 50% of equine veterinarians treat 1-3 fevers per month (~35% treat 6-10 fevers per month) 21

  22. Slide 22: KIND-012 – Pilot Study Results

    KIND-012 – Pilot Study Results Randomized, blinded, placebo-controlled, crossover study (N=31) Primary endpoint was improvement or resolution of fever Response – First dose Response – Crossover Dose 22 Placebo KIND-012 n 16 15 Response Rate (%) 2 (12.5) 10 (66.7) p-value 0.0032 Placebo KIND-012 n 13

  23. Slide 23: KIND-012 – Pilot Study Results

    KIND-012 – Pilot Study Results 23 Mean Temp. over Time - First Dose and Crossover Dose (Treated Pts.) First Dose 6 Hours Post First Dose Crossover Dose 6 Hours Post Crossover Dose Te m pe ra tu re (F ) 97 98 99 100 101 102 103 104 105 106 Scheduled Visit (Hours Relative to First Dose) -5 0 5 10 15 2

  24. Slide 24: KIND-010

    KIND-010 Transdermal drug for the management of weight loss in cats Completing formulation work PK studies completed Initiating pilot study High unmet medical need Current drugs often not effective 90% of veterinarians treat cats with inappetence (average of 7 cats per week) 24

  25. Slide 25: Biologics

    Biologics Highly experienced biologics team Extensive experience developing Lucentis, Xolair, Tysabri, Avastin, Rituxan, Herceptin, Enbrel, and multiple other biologics Internal caninization/felinization/equinization expertise Promising biologics candidates Feline erythropoietin Checkpoint inhibitor

  26. Slide 26: KIND-510 Feline Erythropoeitin

    KIND-510 Feline Erythropoeitin Proprietary recombinant feline erythropoeitin Currently in cell line development Laboratory study starting Strong internal expertise in erythropoeitin biology and engineering High unmet medical need Up to 30% of elderly cats (over 15 years) develop kidney failure, lead

  27. Slide 27: Commercialization

    Commercialization 27

  28. Slide 28: Commercialization

    Commercialization Option A: Launch and commercialize our U.S. products with ~50 person direct sales force Reach the top quartile of the highest prescribing veterinary clinics Use distributors to expand reach Top three national distributors responsible for fulfillment of approximately 70% of U.S. pet

  29. Slide 29: Low Generic Penetration

    Few pet generic companies No automatic substitution Requires sales & marketing effort Rimadyl reached peak sales several years after loss of exclusivity Low Generic Penetration Note: Companion Animal dispensing rate within the veterinary clinic. Source: IMS Health, Putney, BofA Merril Lynch Global R

  30. Slide 30: Exclusivity and IP Position

    Exclusivity and IP Position Full intellectual property protection anticipated for antibody portfolio Use and formulation patents for small molecules 20 years of patent protection from date of filing Regulatory Exclusivity 5 years in U.S. 10 years in E.U. Lifecycle Management New formulations, combin

  31. Slide 31: Business Development

    Business Development In active discussions about acquisitions of businesses and/or assets Ideal candidate: Revenue generating/accretive Commercial infrastructure Complementary assets 31

  32. Slide 32: Financing and Milestones

    Financing and Milestones 32

  33. Slide 33: Select Summary Financials

    Select Summary Financials $ millions For the year ended December 31, 2014 Operating expenses: Research and development $18.7 General and administrative $8.5 Total cash operating expenses (excluding stock-based compensation) $22.8 Total operating expenses (including stock-based compensation) $27.2 To

  34. Slide 34: Summary

    Summary Validated Drugs and Targets $3M-$5M to Market Multiple Approvals Starting within 2 years World Class Team 34

  35. Slide 35: Thank You

    Thank You 35

Kindred Biosciences — Investor Presentation (March 2015) on 6ix